The Chairman, Dr Carrie Hillyard, and Board of UniQuest are delighted to announce the appointment of its new CEO, Dr Dean Moss.
UniQuest is the main commercialisation company of The University of Queensland (UQ), specialising in worldwide technology transfer.
“A global search consultancy firm undertook an international hunt, which produced a number of very high-quality, experienced candidates,” Dr Hillyard said.
“After an exhaustive selection process, Dr Moss was chosen for his experience across science, universities, business, management and commercialisation in Australia, the USA and the UK.”
Dr Moss, who has a PhD in Medicine from UQ, joined UniQuest’s Technology Commercialisation division in 2005 as the General Manager responsible for leadership, business development, and management of the company’s Life Sciences activities, and has been Acting CEO since February 2013.
He has been Managing Director or a senior manager in a number of health and biotech companies worldwide including Agen Biomedical, Binax, Launch Diagnostics, AMRAD Biotech, AMRAD ICT, United Drug and his own successful start-up business in the UK, York Medical Technologies.
Dr Moss has assisted in raising over $75m of venture investment and has held several chair and director roles with UniQuest’s biotech start-up companies including Coridon, Pepfactants, Q-Pharm and Vaxxas.
Dr Moss was part of the management team that worked with UniQuest’s Board in developing its new strategy and has spearheaded its implementation, simplifying the UniQuest business into two business offerings – IP Commercialisation and Expertise Commercialisation.
The company’s revitalised approach aims to optimise the delivery of commercialisation outcomes for UQ, supporting its global strategy and reputation for excellence.
“Under Dean’s capable leadership, we are confident that UniQuest will continue to deliver to industry a quality suite of innovations and expertise capability from researchers at The University of Queensland,” Dr Hillyard said.
More information about Dr Moss is available on the UniQuest website.
About UniQuest Pty Limited
UniQuest is the main commercialisation company of The University of Queensland (UQ), specialising in the commercialisation of intellectual property, research outcomes and expertise. UniQuest delivers commercialisation outcomes which are valuable for UQ and profound for business, the environment, global communities and society as a whole.
UniQuest’s two business offerings – IP Commercialisation and Expertise Commercialisation – are designed to support UQ’s global strategy, industry engagement and reputation for excellence.
UniQuest benchmarks in the top 10 percent globally for university-based technology transfer. UniQuest-licensed UQ innovations are now generating annual sales of $3 billion.
UQ superconductor technology, through licensing arrangements, is used in two-thirds of the world’s MRIs and more than 79 million doses of the life-saving Gardasil® cervical cancer vaccine, patented by UniQuest in 1991, have been distributed throughout 121 countries, including 72 developing countries.
For more information about UniQuest, please visit www.uniquest.com.au.
About The University of Queensland (UQ)
The University of Queensland, Australia, is one of the world’s premier teaching and research institutions. It is consistently ranked in the top 100 in the four leading independent global rankings. With more than 45,000 students and 7500 staff, UQ’s teaching is informed by research, and spans six faculties and eight research institutes.
Media: Nicole Cowan +61 7 3365 4037, +61 407 009 650 or n.cowan@uniquest.com.au
